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Abstract 
Manufacturers of insulin products for diabetes therapy have long sought ways to modify the 
absorption rate of exogenously administered insulins in an effort to better reproduce the naturally 
occurring pharmacokinetics of endogenous insulin secretion. Several mechanisms of protraction 
have been used in pursuit of a basal insulin for which a low injection frequency would provide 
tolerable and reproducible glucose control; these mechanisms have met with varying degrees of 
success.  
Before the advent of recombinant DNA technology, development focused on modifications to the 
formulation that increased insulin self-association, such as supplementation with zinc or the 
development of pre-formed precipitates using protamine. Indeed, neutral protamine Hagedorn 
insulin remains widely used today despite a frequent need for a twice-daily dosing and a relatively 
high incidence of hypoglycaemia.  
The early insulin analogues used post-injection precipitation (insulin glargine U100) or dimerization 
and albumin binding (insulin detemir) as methods for increasing therapeutic duration. These 
products approached a 24-hour glucose-lowering effect with decreased variability in insulin action. 
Newer basal insulin analogues have used up-concentration in addition to precipitation (insulin 
glargine U300), and multihexamer formation in addition to albumin binding (insulin degludec), to 
further increase duration of action and/or decrease the day-to-day variability of the glucose-
lowering profile. Clinically, the major advantage of these recent analogues has been a reduction in 
hypoglycaemia at similar HbA1c control when compared with earlier products.  
Future therapies may bring clinical benefits through hepato-preferential insulin receptor binding or 
very long durations of action, perhaps enabling once-weekly administration and the potential for 
further clinical benefits. 
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Introduction 
Endogenous insulin is stored as hexamers – formed by three dimers combining with two zinc ions – 
together with cargo ions, molecules and proteins in beta-cell vesicles of the pancreas. Once released 
into the bloodstream, hexamers rapidly dissociate into biologically active monomers [1]. Secretion of 
endogenous insulin is dynamic in response to physiological need, but there is typically a constant 
‘basal’ level of insulin secretion upon which rapidly produced prandial peaks of secretion in response 
to food intake are superimposed. The absorption kinetics of unmodified human insulin following 
subcutaneous injection, however, match neither the physiological basal nor the prandial secretion 
fully because of the rate at which the injected hexamers dissociate into the smaller dimers and 
monomers, which in turn are able to penetrate capillary membranes. Therefore, manufacturers have 
sought ways to modify the absorption kinetics of exogenously administered insulin to more 
accurately reproduce the dynamic insulin profile of normal physiology. Consequently, fast-acting 
insulin products are available that are given at meal times to suppress postprandial blood glucose 
excursions, while long-acting basal insulin products provide a constant suppression of hepatic 
glucose release between meal times and overnight [1].  
 
In the case of developing basal insulins, the absorption rate needs to be slowed as much as possible, 
thereby permitting a low injection frequency that produces a steady-state profile with a low 
peak:trough ratio [2]. The major challenge in developing such a basal insulin is to achieve stable 
release profiles, thereby allowing reproducible glucose control. 
 
Various approaches have been made to modify the native insulin molecule and/or its formulation to 
develop safe and efficacious basal insulin products. These include re-formulation (e.g. cobalt 
substitution of zinc, higher zinc concentration), precipitation, protein binding (namely albumin), up-
concentration of formulations (including the up-concentration of insulins with additional protraction 
mechanisms), the formation of higher-order structures after injection (e.g. multihexamer chains and 
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precipitates), PEGylation, and conjugation to non-glycosylated human Fc. The impact of these 
different modes of protraction on the resulting pharmacokinetic (PK)/pharmacodynamic (PD) 
profiles and, ultimately, clinical outcomes is reviewed here, along with possible future strategies. 
 
Insulins and formulations engineered for increased self-association 
NPH insulin 
Precipitation, as a mechanism of protraction of insulin action, was first successfully achieved by the 
addition to the formulation of protamine, together with zinc [3]. The resulting intermediate-acting 
insulin, neutral protamine Hagedorn (NPH), is protracted by being injected as a suspension of pre-
formed protein–insulin conglomerates, formed from insulin and protamine in a 5:1 molar ratio [4].  
 
Upon injection, the solvent from NPH insulin suspensions diffuses freely into the subcutaneous 
tissue, much as soluble insulin would following injection, but the insulin crystals are retained in 
‘heaps’ at the injection depot (Figure 1) [5,6]. These ‘heaps’ dissolve slowly, hence NPH action is 
protracted. However, the conglomerates of protein and insulin under the skin vary in shape and size; 
therefore, so too do the absorption kinetics, from one injection to another, according to the depot 
environment and injection technique [6]. Invading macrophages and protamine-splitting enzymes in 
the subcutaneous tissue are thought to be responsible for dissolution of NPH insulin heaps and are 
one example of a variable present in the injection environment [6].  
 
Another major source of variability in the PK/PD profile of NPH arises because the product requires 
adequate resuspension (e.g. by rolling the vial 20 times) before subcutaneous injection. Failure to 
achieve resuspension can alter the PK/PD profile in different ways, depending on the angle at which 
the injection device was stored [7,8].  
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Although the duration of action of NPH is protracted compared with regular soluble insulin, it is 
typically only 12–14 h in total, and this relatively short duration is associated with a peak effect at 4–
6 h, gradually declining thereafter. Therefore, NPH usually requires at least twice-daily dosing to 
ensure that basal insulin levels are sustained across 24 hours [9,10]. Variability in both resuspension 
technique and the formation and dissolution of the precipitate contribute to the substantial 
injection-to-injection variability in PD profiles observed for individuals treated with NPH [8,11]. 
Consequently, hypoglycaemia – particularly nocturnal hypoglycaemia, resulting from unpredictability 
in the nocturnal insulin peak following evening administration – is a common issue for patients 
treated with NPH [12]. Nevertheless, NPH insulin is a low-cost product that remains widely used 
today [13]. 
 
Lente insulins 
Hallas-Møller and colleagues first developed the Lente insulin suspensions in the 1950s by 
complexing animal-derived insulin suspensions with small amounts of zinc. Insulin action was 
protracted due to the slow dissolution of crystals [14]. Advantage was taken of the different 
solubilities of bovine and porcine insulin at neutral pH to create a trilogy of zinc–insulin suspensions: 
Lente (3:7 mixture of amorphous porcine insulin and bovine crystalline particles with an 
‘intermediate’ duration of action similar to that of NPH), Semilente (amorphous insulin particles) and 
Ultralente (large bovine crystalline particles providing the first ‘long’-acting insulin preparation) [15]. 
The Lente insulins were reformulated to use recombinant human insulin following the advent of 
commercial production of human insulin in the 1980s, but they remained limited by their ≤24-hour 
duration of action [9], the need for resuspension, and their highly variable action profile. Another 
limitation, more so before the advent of the insulin pen device, was that Lente insulins could not be 
mixed with human soluble insulin. This is in contrast to NPH, the absorption kinetics of which are 
unaffected when mixed with human insulin [16]. 
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Co(III) insulin 
A subsequent strategy, which did not make it to clinical practice, was to strengthen insulin hexamers 
by substituting the zinc ions with cobalt (Co) [17]. While Co(III) insulin did behave as predicted, with 
the hexamers being slower to dissociate, it offered no real pharmacological advantages over NPH 
insulin [18]. Instead, alternative strategies were undertaken, including modifying the amino acid 
sequence of the insulin itself to produce insulin analogues. 
 
Precipitation after injection 
In pursuit of a more stable and protracted release formulation, research focused on shifting the iso-
electric point of insulin by altering the insulin molecule itself to enable precipitation at physiological 
pH after injection. This approach enables the insulin to be injected as a solute (in a slightly acidic 
formulation) that forms precipitates (of various sizes) in the neutral environment of the subcutis 
(Figure 1). The process therefore avoids the problems associated with resuspension.  
 
NovoSol Basal 
NovoSol Basal was the first insulin analogue to employ this mechanism of protraction by virtue of 
two amino acid substitutions (B27Arg, A21Gly) and amidation of the C-terminal of the human insulin 
B chain (Figure 2) [19]. Following injection, <5 μm crystals form and slow absorption follows, such 
that the T50% of NovoSol Basal – namely the time elapsed until 50% of injected radio-labelled insulin 
has disappeared from the depot – is significantly longer than that of Ultratard HM, a long-acting 
human insulin (35.3 vs. 25.5 h, p < 0.001) [20]. NovoSol Basal was also shown to result in less within-
patient variation versus Ultratard HM, but between-patient variation remained high. As 
bioavailability was markedly reduced with NovoSol Basal versus Ultratard HM, necessitating high 
doses, and as NovoSol Basal was also associated with local inflammatory reactions, it was withdrawn 
from further studies [21–23]. 
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Insulin glargine U100 
Insulin glargine 100 units/ml (IGlar U100) was the first basal insulin analogue approved for clinical 
use. It is engineered to have an iso-electric point of pH 6.7, achieved by substituting glycine A21 on 
the A chain of human insulin for asparagine, and adding two asparagine molecules to the amino 
terminal of the B chain (Figure 2) [24,25]. The post-injection precipitation of IGlar U100 results in a 
longer, flatter time–action profile versus NPH [25,26]. The mean duration of IGlar U100 action – 
namely the time between injection and blood glucose levels rising again in clamp studies to reach 
8.3 mmol/l (150 mg/dl) [26] – has been reported to be 22–24 h under single-dose conditions [9,11] 
and 24–25.6 h under steady-state conditions [27,28], with a gentle rise and fall in the PK/PD profile 
across this interval [26,28]. Consequently, once-daily dosing is effective in most patients, although 
not all [26,29]. There is evidence of a waning of effect over 24 h with once-daily IGlar U100 [30] and 
clinical studies have confirmed that glycaemic control can be further improved in some patients with 
type 1 diabetes with twice-daily dosing of IGlar U100 [29,31]. 
 
Precipitation itself is inherently variable [6] and so, although IGlar U100 is associated with less 
within-subject variability than NPH in clinical practice, where patient adherence to resuspension 
protocol varies [7], the problem of a variable PK/PD profile from injection to injection is not 
completely eliminated [11]. A repeat-clamp study in which IGlar U100 was compared with NPH 
(given after controlled resuspension) did suggest reduced variability in the injection-to-injection PD 
profile with IGlar U100 versus NPH, although this was not statistically tested [11]. In clinical studies, 
once-daily dosing of IGlar U100 resulted in lower risks for nocturnal hypoglycaemia versus once- or 
twice-daily dosing of NPH in patients with type 1 [32] and type 2 diabetes [33–35], and IGlar U100 is 
now the most widely used basal insulin worldwide. However, while the mean PK/PD and variability 
profiles of IGlar U100 represent welcome improvements upon those of NPH that translate into 
clinical advantages, the within-patient injection-to-injection variability of IGlar U100 remains 
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relatively high compared with more recently developed basal insulins such as insulin detemir [11], 
insulin degludec [36] and PEGylated insulin lispro [37].  
 
Protein-bound insulin analogue: insulin detemir 
There are several properties unique to insulin detemir (IDet) compared with other insulins, although 
the possible connection between these properties and IDet’s mechanism of protraction has yet to be 
fully elucidated. Insulin detemir is a pH-neutral, soluble insulin analogue that is acylated at residue 
B29-lysine with a 14-carbon myristoyl fatty acid. This facilitates self-association of IDet molecules at 
the injection depot as dihexamers, and reversible binding to albumin, thereby slowing its systemic 
absorption (Figure 1) [38,39]. The mean duration of action for IDet (using the same definition as for 
IGlar U100 above) was calculated to be 21.5 h in patients with type 1 diabetes, hence slightly shorter 
than for IGlar U100, based on data for a 0.4 U/kg dose level in a single-dose clamp study [10,26]. 
However, a head-to-head, double-blind clamp study showed no appreciable difference in duration of 
effect at clinically relevant doses in patients with type 2 diabetes who still had some (although low) 
endogenous insulin secretion capacity [27].  
 
The observational study PREDICTIVETM demonstrated that, similar to IGlar U100, once-daily dosing of 
IDet is possible for some patients with type 1 diabetes, but many require twice-daily dosing [40]. 
Compared with IGlar U100 and NPH, IDet produces significantly lower (between two- and four-fold 
lower) within-patient variability in the glucose-lowering response from injection to injection, as 
shown in a large-scale, repeated clamp study [11] and a crossover trial involving 32 children or 
adolescents with type 1 diabetes [41]. This may be partly attributable to the reversible binding of 
IDet to albumin in the circulation, buffering changes in absorption rate caused by changes in local 
blood flow at the depot [18,27,38]. 
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Insulin detemir therefore provides more predictable glycaemic control with consistent risk 
reductions for hypoglycaemia and less weight gain versus NPH in clinical trials [26,39]. The majority 
of studies comparing IDet and IGlar U100 show similar rates of hypoglycaemia [42–46], with the 
exception of Pieber et al. [47] who showed a benefit of twice-daily IDet in nocturnal hypoglycaemia 
compared with once-daily IGlar U100.  Less weight gain for IDet versus IGlar U100 is consistently 
observed, ranging from 25% up to 50% less weight gain with IDet, with this advantage being greatest 
when IDet is dosed once daily. The reasons for this relative reduction in weight gain are not yet 
understood, but might be related to a slight hepato-preferential effect [48] or satiety effects on the 
central nervous system [49]. 
  
Insulin detemir is formulated at four-times the concentration of human insulin because it has a 
lower molar potency than human insulin and other insulin analogues [50]. It has been proposed that 
this might reflect the reduced affinity of IDet for the insulin receptor [18]; however, a reduced molar 
potency in glucose-lowering effect is generally not seen with other insulin analogues that have a 
reduced receptor-binding affinity, nor in other albumin-binding analogues. The reasons for the 
reduced molar potency of IDet have therefore yet to be elucidated. From a clinical perspective, 
however, the important point here is that one unit of IDet is defined as 24 nmol, as opposed to 6 
nmol for other insulins, but this has a similar total blood glucose-lowering effect to one unit of other 
insulins [18]. The increased molar concentration of IDet therefore facilitates unit-for-unit switches 
between basal insulins, and should not be confused with the up-concentration of other basal insulins 
(described below) that has been used as a method of increasing duration or reducing injection 
volume.   
 
Multihexamer chain formation: insulin degludec  
Insulin degludec (IDeg) is an analogue in which threonine has been removed at B30 and B29 has 
been acetylated with a 16-carbon fatty diacid via a glutamic acid spacer. This change confers a 
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slower rate of absorption to IDeg by enabling formation of high-molecular-weight complexes, and 
albumin binding following subcutaneous injection. IDeg forms highly stable dihexamers (closed 
configuration) in phenol- and zinc-containing formulation due to an interaction between one of the 
fatty diacid side chains of one hexamer and a zinc atom of another (Figure 3) [51–53]. In the absence 
of phenol, as will occur after injection, the IDeg dihexamers change to adopt an open configuration 
allowing for the multihexamer chains to form, as shown by size-exclusion chromatography [2]. The 
dihexamers link up to form these multihexamer chains, again by the interaction of fatty diacid chains 
and zinc atoms between adjacent hexamers [54]. Subsequent diffusion of zinc from each terminal of 
the chain causes the terminal hexamers to break apart into dimers, which then dissociate into 
monomers. This process results in a steady and gradual release of monomers, which are absorbed 
into the systemic circulation [2,55].   
 
In a head-to-head, 42-h glucose clamp study in patients with type 1 diabetes, mean half-life of IDeg 
100 units/ml (U100) was 25.4 h versus 12.1 h for IGlar U100, with at least a 42-h duration of IDeg 
U100 action at steady state using once-daily administration of 0.4 U/kg [56]. The coefficient of 
variation of glucose-lowering effect of IDeg U100 was four-times lower than for IGlar U100 at the 
same dose (20% vs. 82%), with a more even distribution of the glucose-lowering effect over 24 h 
[36,57]. 
  
Importantly, once-daily dosing of the same dose of an insulin analogue with a duration of action >24 
h will not result in excessive accumulation or ‘stacking’ in the patient. Rather, the serum insulin 
concentration will accumulate slowly until a very flat, steady-state profile is reached in 3–5 days. It is 
therefore important to note that patients should allow 3 days before performing dose adjustments 
[58]. 
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IDeg U100 provided glycaemic control with a reduced risk of nocturnal hypoglycaemia versus IGlar 
U100 for patients with type 1 diabetes and patients with type 2 diabetes in the phase 3 clinical trial 
programme [59] and in subsequent 64-week, double-blind, crossover trials (SWITCH 1 [60] and 
SWITCH 2 [61]). A pre-specified meta-analysis of patient-level data revealed a significantly lower risk 
of overall confirmed (17% lower) and nocturnal confirmed hypoglycaemic events (32% lower) for 
patients with type 2 diabetes receiving IDeg U100 versus IGlar U100 [59]. The rate of nocturnal 
confirmed hypoglycaemic events was also significantly 25% lower for IDeg U100 versus IGlar U100 in 
the type 1 diabetes population (where rapid-acting mealtime insulins are routinely used), whereas 
the rate of overall confirmed hypoglycaemia was trending higher, although it did not reach statistical 
significance. In both populations, treatment differences were more pronounced after 16 weeks of 
IDeg U100 initiation, when the insulin doses had reached stable levels [59]. A separate meta-analysis 
of additional endpoints in the clinical trial programme demonstrated that, in both the pooled basal–
bolus-treated type 1 diabetes and pooled insulin-naïve type 2 diabetes trial populations, the lower 
rates of hypoglycaemia were achieved with a significantly 12% and 10% lower insulin dose versus 
IGlar U100, respectively [62]. Similar risk reductions were observed in subsequent 64-week, double-
blind, crossover trials in which IDeg U100 resulted in significantly lower hypoglycaemia (overall, 
severe and nocturnal) throughout the trial period versus IGlar U100 in patients with type 1 diabetes 
[60] and in patients with type 2 diabetes [61] who were at high risk of hypoglycaemia. 
 
Also of clinical importance is the suitability of IDeg U100 for dosing any time of day, by virtue of its 
long duration of action and flat, predictable PD profile. This capability has been demonstrated in two 
26-week, open-label, treat-to-target trials in type 1 and type 2 diabetes trial populations in which 
IDeg U100 given in a ‘forced-flexible’ schedule (with minimum 8, maximum 40 h between doses) was 
compared with IDeg U100 or IGlar U100 given at the same time daily [63,64].  
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The formation of stable dihexamers in formulation also offers the potential for IDeg U100 to be co-
formulated with the rapid-acting analogue insulin aspart without hybrid hexamers forming [65], or 
with liraglutide, a glucagon-like peptide-1 receptor agonist. The clinical utility of these fixed-
combination products has been demonstrated in several type 2 diabetes patient populations [66,67]. 
  
Impact on the PK/PD profile of up-concentrated formulations 
The impact of up-concentration on insulin absorption has long been observed with regular mealtime 
insulins and has since been employed to further protract the absorption of basal insulin analogues. 
For example, Humulin® R U-100 has a significantly shorter duration of action and a higher peak 
effect versus its up-concentrated formulation, Humulin® R U-500 [68], which, at least at very high 
doses, has a blood glucose-lowering effect lasting 21 hours. Onset of action, however, remains 
comparable such that dosing 30 minutes before mealtime is suitable for both concentrations [68]. 
This phenomenon, whereby up-concentration of regular insulin results in a longer action profile, is 
explained by the observation that more compact conglomerates are formed: absorption is slowed 
because the surface area from which absorption can occur is reduced and there is a greater distance 
from this surface to capillaries [69]. The availability of up-concentrated, lower-volume basal insulin 
formulations in devices capable of delivering more than 80 units per dose offers the possibility of 
fewer injections for patients requiring high doses of basal insulin. However, because of the 
alterations in the PD profile and potential changes in bioavailability, studies have investigated 
whether switching to the up-concentrated formulation may require adjustments to dose and 
regimen. 
 
Insulin glargine U300 
When concentrating IGlar U100 to 300 U/ml (IGlar U300) for the purpose of being able to administer 
higher insulin doses in smaller volumes, the expected protraction in action profile was observed. 
After 1 week at steady state (0.4 units/kg/day), the half-life was 19.0 h for IGlar U300 versus 13.5 h 
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for IGlar U100 [70]. Importantly, the PK/PD profile was flatter than that of IGlar U100 and the 
duration of action extended upwards to 32 h in patients with type 1 diabetes [70]. A duration of 
action that extends beyond 24 h is advantageous as it means that with once-daily dosing, circulating 
insulin concentrations will rise over a few days until a steady-state profile with a low peak:trough 
ratio is reached. This reduces waxing and waning of effect, thereby reducing the risk of 
hypoglycaemia [58]. It is also important to note, however, that a significant 27% relative reduction in 
the biopotency of IGlar U300 at steady state was observed in this study versus IGar U100 [70]. 
Therefore, IGlar U100 and U300 are neither bioequivalent nor directly interchangeable, and a 
patient switching to the up-concentrated formulation will need to adjust dose accordingly [71]. The 
definition of a unit of IGlar U300 does not take the lower biopotency of IGlar U300 versus IGlar U100 
into account, and therefore higher doses of IGlar U300 versus IGlar U100 would be expected. This 
was found to be the case in clinical trials, with a 12% higher dose of IGlar U300 required after 6 
months [72], and a 44% higher dose increase than with IGlar U300 over 1 year [73]. 
 
Results from a post hoc meta-analysis of EDITION I–III, in which the safety and efficacy of IGlar U100 
and IGlar U300 were compared in patients with type 2 diabetes, reported that non-inferiority of 
IGlar U300 compared with IGlar U100 regarding fasting plasma glucose and HbA1c reduction was 
achieved within 12 weeks. Superiority of IGlar U300 over IGlar U100 in terms of hypoglycaemia was 
confirmed in the meta-analysis with a significantly lower relative risk (RR) of overall (confirmed [≤3.9 
mmol/l {≤70 mg/dl}] or severe) hypoglycaemia (RR 0.86 [0.74; 0.97]95% CI) for the total duration of the 
trial. The study’s titration phase was defined as ending at week 9; however, insulin dose did not 
stabilize until week 16 [72]. Nevertheless, while IGlar U300 showed a significant reduction in the rate 
of confirmed overall and nocturnal hypoglycaemia during the titration phase in a post hoc analysis, 
only the difference in nocturnal hypoglycaemia risk reduction reached statistical significance in the 
period from week 9 to end of study (pre-defined study endpoint). Thus, once the doses of IGlar U300 
and IGlar U100 are equipotent, the cumulative mean number of hypoglycaemic events run in parallel 
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to one another. This pattern is in contrast to the IDeg U100 versus IGlar U100 trials, in which the 
relative risks for hypoglycaemia did not tend to diverge until after 16 weeks of treatment, when the 
doses had been titrated to near-final levels [72].  
 
Insulin degludec U200 
An up-concentrated formulation, IDeg U200 (200 U/ml), is also available. Of interest, and in contrast 
to IGlar, the two IDeg concentrations (100 U/mL and 200 U/mL) are comparable in terms of PK and 
PD parameters [74]. In a post hoc analysis, the 90% confidence intervals for area under the serum 
IDeg U100 and U200 concentration–time curves and maximum IDeg U100 and U200 concentrations, 
at steady state during a dosing interval, were within the limits for bioequivalence (0.80–1.25) [74]. 
The glucose-lowering effects of IDeg U100 and IDeg U200 were both evenly distributed between the 
first and second 12 h post-dosing. Therefore, one can switch from IDeg U100 to IDeg U200 and 
maintain glycaemic control without changing the dose administered or the regimen used. 
 
A 26-week, open-label, treat-to-target trial compared the safety and efficacy of IDeg U200 with IGlar 
U100 in insulin-naïve patients with type 2 diabetes and demonstrated that IDeg U200 was non-
inferior to IGlar U100 in terms of HbA1c reduction, and that the rates of both overall and nocturnal 
hypoglycaemia were comparable [75]. This was achieved at an 11% lower end-of-trial daily insulin 
dose for IDeg U200 patients versus IGlar U100 [75]. 
  
The reason why up-concentration of IGlar U100 alters its time–action profile and potency whereas 
IDeg U100 and IDeg U200 are interchangeable has yet to be elucidated, but likely reflects differences 
in mechanism of protraction. As noted above, for insulin analogues that precipitate, up-
concentration further delays absorption of a given dose by creating larger precipitates and thereby 
reducing the surface area from which absorption can occur [68,76]. In contrast, the mechanism of 
protraction of IDeg is such that the release of zinc from multihexamer chains is the rate-limiting step 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
for IDeg absorption [2,77]. This rate may be inherently less affected by concentration; however, the 
zinc concentration of IDeg U200 has been optimized to increase its bioequivalence to the U100 
formulation [77]. 
 
An ongoing, randomized, double-blind, multiple-dose, two-period crossover trial will compare PK/PD 
properties of IDeg U200 and IGlar U300 at steady state in type 1 diabetes [78]. 
 
Other strategies 
PEGylation 
PEGylation is the process of attaching polyethylene glycol (PEG) polymer chains to a molecule to 
increase its hydrodynamic size. This principle was studied as a potential protraction mechanism for 
insulin with a PEGylated version of insulin lispro. Trials yielded some promising results prior to Eli 
Lilly and Company’s decision at the end of 2015 to end the clinical development programme. 
PEGlispro had a long half-life of 2–3 days in patients with type 2 diabetes, as a result of both 
prolonged absorption and reduced clearance [79,80]. 
  
A randomized crossover study conducted in eight healthy male subjects revealed a hepato-
preferential effect and relatively decreased peripheral action of PEGlispro on glucose homeostasis 
that might better recreate the physiological actions of endogenous insulin, which is secreted into the 
portal vein [81]. In the open-label IMAGINE 1 trial, patients receiving PEGlispro reported a 
statistically significant higher rate of severe hypoglycaemic events (estimated rate ratio: 2.50).  
However, in the larger, blinded IMAGINE 3 trial the rate of severe hypoglycaemic events for 
PEGlispro treatment was numerically lower than for IGlar U100 (19.7 events/100 patient-years of 
exposure [PYE] vs. 22.5 events/100 PYE), but not statistically significant [82,83]. In a 52-week trial 
comparing safety and efficacy of PEGlispro versus IGlar U100 in patients with type 2 diabetes 
uncontrolled on basal insulin or ≥3 oral antidiabetic drugs, PEGlispro provided superior HbA1c 
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reductions (least squares mean difference –0.52% [–0.67; –0.38]95% CI, p < 0.001) at a 60% lower rate 
of nocturnal hypoglycaemia, but with higher mean [SD] levels of triglycerides (174 mg/dl [4] vs. 158 
mg/dl [6]), alanine aminotransferase (34.3 IU/l [0.8] vs. 26.4 IU/l [1.1]), aspartate aminotransferase 
(27.7 IU/l [0.6] vs. 23.5 IU/l [0.8]) and liver fat content (14.9% [0.5] vs. 9.6% [0.8]) versus IGlar U100 
after 52 weeks of treatment [37]. PEGlispro was associated with less weight gain versus IGlar U100 in 
patients with type 2 diabetes not previously using insulin (IMAGINE-2) [84], those using basal insulin 
with mealtime insulin (IMAGINE-4) [85], and similar weight gain versus IGlar U100 in patients 
currently using a basal insulin (IMAGINE-5) [37]. 
 
Future development of PEGylated insulin analogues (or hepato-preferential basal insulin per se) will 
have to address possible regulatory concerns about liver fat accumulation. 
 
Conjugation to the non-glycosylated Fc portion of human IgG 
Hanmi Pharmaceuticals has introduced a novel way of protracting the time–action profile of proteins 
by conjugating them to the non-glycosylated Fc portion of human IgG via a short, flexible linker [86]. 
The project is still early in development, but results from animal studies have been promising, 
indicating that it might be possible to extend the duration of insulin action beyond 7 days and move 
towards once-weekly dosing [87,88]. Further data on this novel mechanism of protraction will be of 
great interest, in particular with regard to safety, but also with regard to PK/PD and clinical efficacy. 
 
Summary 
Several mechanisms of protraction have been used to improve the PK/PD characteristics of basal 
insulins and all have resulted in prolonged action to varying extents. The early basal insulin 
analogues, IGlar U100 (precipitation) and IDet (dimerization and albumin binding), increased 
duration such that it approached a 24-h glucose-lowering effect, and improved the level of day-to-
day and intra-patient variability in insulin action. Newer basal insulin analogues have used up-
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concentration in addition to precipitation (IGlar U300), and multihexamer formation in addition to 
albumin binding (IDeg U100 and U200). The latter mechanism has resulted in a further increase in 
duration of action and decreased variability versus other available basal insulin therapies. Clinically, 
the major advantage of these analogues has been a reduction in hypoglycaemia at similar HbA1c 
control. The recent development of hepato-preferential or very long-acting (once-weekly) insulins 
promises the potential to achieve further clinical improvements, but safety of these new 
preparations and clinical applicability remains to be demonstrated. 
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Figure 1. Summary of the different mechanisms of protraction 
 
 
 
Figure 1 depicts how absorption of different insulin therapies is protracted. NPH insulin is injected as 
a pre-formed protein–insulin conglomerate. Upon injection, the solvent from NPH insulin 
suspensions diffuses freely into the subcutaneous tissue but the crystals are retained in ‘heaps’ at 
the injection depot. IGlar U100 is soluble in acidic formulation but, upon subcutaneous injection and 
reaching physiological pH, it forms crystals. IGlar U300 also precipitates at physiological pH but these 
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precipitates are much more compact compared with those of IGlar U100, so the surface area from 
which absorption can occur is reduced, thereby further slowing absorption. Acylation of IDet with a 
fatty acid side chain facilitates self-association of IDet at the injection depot as dihexamers and 
reversible binding to albumin, both in the depot and in circulation, thereby slowing its absorption. 
Insulin degludec also has a fatty acid side chain, which facilitates dihexamer formation in the vial and 
albumin binding in the circulation. However, protraction of absorption is primarily achieved via 
multihexamer chain formation in the depot. Subsequent dissociation of zinc causes the terminal 
hexamers to break down. The large hydrodynamic size of PEGlispro prolongs its action by slowing 
absorption and reducing clearance, effectively producing a circulating depot. The PEGlispro clinical 
trial programme was terminated in 2015.  
IDet, insulin detemir; IGlar, insulin glargine; NPH, neutral protamine Hagedorn. 
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Figure 2. Molecular structure of insulin analogues 
 
 
Figure 2 depicts molecular modifications made to the human insulin molecule in order to protract 
action. The isoelectric point of IGlar U100 was raised by substituting glycine 21 on the A chain (A21) 
of human insulin for asparagine, and adding two asparagine molecules to the amino terminal of the 
B chain. IDet is an analogue in which threonine B30 has been removed and lysine B29 is acylated 
with a 14-carbon myristoyl fatty acid. Threonine B30 is also removed in IDeg but lysine B29 is 
attached to a 16-carbon fatty diacid via a glutamic acid spacer. In PEGlispro, the order of proline and 
lysine is reversed such that proline 29 follows lysine 28, which is attached to a polyethylene glycol 
chain via a urethane bond. 
IDeg, insulin degludec; IDet, insulin detemir; IGlar U100, insulin glargine 100 units/mL. 
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Figure 3. IDeg dihexamer formation [51–53] 
 
 
Insulin hexamers are arranged such that they have two poles, each formed by three of the 
constituent monomers, and these poles can be ‘open’ (to expose the zinc-containing core of the 
hexamer) or ‘closed’ (shielding the core). In the presence of phenol or phenolic derivatives, which 
bind to hydrophobic pockets of the hexamers, the poles are closed [51–53]. Two IDeg hexamers link 
together to form stable dihexamers, by the interaction of a single fatty diacid chain from one 
hexamer with a zinc atom of a neighbouring hexamer. Upon subcutaneous injection, these 
dihexamers link up to form multihexamer chains in the same manner because depletion of phenol 
after injection causes the closed poles to open, thereby exposing the second zinc ion. Ultimately, 
diffusion of zinc causes the terminal hexamers of these chains to break down into dimers, which 
then dissociate into monomers. 
IDeg, insulin degludec; Zn, zinc. 
 
Figure adapted from Jonassen et al. [2]. Republished with permission of Springer New York LLC; 
permission conveyed through Copyright Clearance Center, Inc.  
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